Login
Related Links
Advertise on this site?
Advertising opportunities on Gene Therapy Net include standard size banners as well as text ads. Click here for more information about advertising.
You can also make a donation by PayPal and support the Gene Therapy Net website.
Companies - V
VBL Therapeutics VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biotechnology company focused on the discovery, development and commercialization of first in class treatments for cancer. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program. VBL is based in Tel Aviv, Israel. |
|
Vector Gene Technology Company, Ltd. VGTC is a leader in recombinant adeno-associated virus (rAAV) large-scale manufacturing. Its novel AAV package and purification systems make the producing of AAV to be one of the most cost-effective AAV producing systems. |
|
Vical Incorporated Biotechnology company developing biopharmaceutical products based on DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, like infections diseases and cancer. |
|
VirRx, Inc. Biotechnology company with a primary interest in cancer gene therapy. Its broad mission is to develop genetically modified "smart bomb" adenoviruses for use in treating human cancers. |
|
VIVEbioTECH S.L. A Spanish biotech company which specialises in gene transfer technologies, and in particular those related to the production of viral vectors under GMP conditions, and their gene therapy applications. |
|
Information Companies
Overview of biotechnology companies involved in gene therapy and/or cell therapy, as well as contract research organizations (CRO) and medical supply companies.
The provided information about the companies is just a summary of the information giving on their websites and is therefore not always complete, correct and/or exhaustive. Please visit the companies websites for a complete picture of the company.
Your company not listed? Click here to submit.
Like to work for a company? Find here the perfect job in gene therapy.
Gene Therapy News
- RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study - MD Magazine
Thu, 28 Mar 2024 23:12:1 GMT - Nanoscope targets FDA approval following positive gene therapy trial results - Longevity.Technology
Thu, 28 Mar 2024 19:17:3 GMT - FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy - JD Supra
Thu, 28 Mar 2024 17:52:4 GMT - Cell And Gene Therapy Manufacturing Services Market Set To - GlobeNewswire
Thu, 28 Mar 2024 16:31:4 GMT - Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033 - BioSpace
Thu, 28 Mar 2024 16:06:0 GMT - Trial will test gene therapy for limb-girdle muscular dystrophy type - Muscular Dystrophy News
Thu, 28 Mar 2024 15:27:2 GMT - REGENXBIO reports promising gene therapy for eye disease - Investing.com
Thu, 28 Mar 2024 14:22:1 GMT - Cell therapy weekly: Clinical Trial Application Approval for Muscular Dystrophy Gene Therapy - RegMedNet
Thu, 28 Mar 2024 13:58:0 GMT - REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III - Genetic Engineering & Biotechnology News
Thu, 28 Mar 2024 12:05:1 GMT - Robots and AI: The Future of Cell and Gene Therapy Manufacturing - Genetic Engineering & Biotechnology News
Wed, 27 Mar 2024 17:00:2 GMT - Gene therapy offers hope for giant axonal neuropathy patients - UT Southwestern
Wed, 27 Mar 2024 16:52:2 GMT - Gene Therapy, DNA's Past, RNA's Future: Early History - Forbes
Wed, 27 Mar 2024 16:20:5 GMT - Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint - BioSpace
Wed, 27 Mar 2024 16:18:4 GMT - Atamyo's gene therapy for LGMD2C/R5 cleared to enter clinic in Europe - BioWorld Online
Wed, 27 Mar 2024 14:00:0 GMT - Intellia ending work with Regeneron on hemophilia B gene therapy - Hemophilia News Today
Wed, 27 Mar 2024 13:35:0 GMT